Healthcare partnership launches medical device for asthmatics

A healthcare supplier in Leeds has worked alongside technology provider Bosch to launch a breath analysis device for sufferers of asthma.

Healthcare 21 was chosen by Bosch to launch the company’s first medical device for asthma patients, Vivatmo. The device measures the levels of exhaled nitric oxide and helps monitor patients’ treatment and adherence.

The device is also available in a version designed for use by healthcare professionals. Vivatmo detects levels of exhaled nitric oxide by using a sensor called FeNO – fractional exhaled nitric oxide.

David Plotts, business development director for Healthcare 21 said: “We were absolutely delighted to be approached by Bosch Healthcare Solutions, who were aware of our expertise in launching a product like this in the UK and Ireland and our experience in working with NICE on the roll out of FeNO for clinicians and patients.

“This is an exciting product which has far reaching benefits for both doctors and for the first time, asthma patients themselves, who are now able to buy this device and use it at home and have more control over their condition and treatment.”

Marc Meier, general manager of Bosch Healthcare Solutions, said: “We are very pleased to be working with  Healthcare 21 to launch our first medical device in the UK and Ireland for doctors and patients alike.

“Vivatmo, for the first time gives asthma patients more real-time information about their condition. It is easy to use at home as part of a daily routine to regularly measure FeNO and monitor a patient’s asthma, in a similar way a person with diabetes would monitor their blood sugar. The Vivatmo technology enables a patient to monitor which individual factors improve or worsen their asthma and in turn, this can give them more confidence in managing their condition.”